{"id":"118500617129-29","name":"H. Lundbeck A/S","registrationDate":"2015-04-27T16:44:12.323+01:00","category":2,"subCategory":3,"legal":"Corporation","web":"http://www.lundbeck.com","country":"Denmark","headAddress":"Ottiliavej 9","headCity":"Valby","headPostCode":"2500","headPhone":"(45)36 30 13 11","boss":"Anders GÃ¶tzsche","bossTitle":"Mr","bossPosition":"Interim CEO","membersCount":1,"membersFTE":"0.25","membership":"Efpia - European Federation of Pharmaceutical Industries and Associations&#xd;\nhttp://www.efpia.eu/&#xd;\n&#xd;\nDI - Confederation of Danish Industry&#xd;\nhttp://di.dk/English/Pages/English.aspx&#xd;\n&#xd;\nEBC- European Brain Council &#xd;\nhttp://www.europeanbraincouncil.org/","memberOrga":"","goal":"H. Lundbeck A/S is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.&#xd;<br />&#xd;<br />Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).&#xd;<br />&#xd;<br />For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.","acronym":"HLU","interests":"Public Health, Research and Technology","euInitiatives":"initiatives relevant for the pharmaceutical industry","lastUp":"2018-02-26T10:11:42.567+01:00","customers":"","costAbsolu":"","costRange":"0-9999","turnoverAbsolu":0,"turnoverRange":""}